Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.

Authors: Teng, Hao-Wei  Huang, Yu-Chung  Lin, Jen-Kou  Chen, Wei-Shone  Lin, Tzu-Chen  Jiang, Jeng-Kai  Yen, Chueh-Chuan  Li, Anna Fen-Yau  Wang, Hsei-Wei  Chang, Shih-Ching  Lan, Yuan-Tzu  Lin, Chun-Chi  Wang, Huann-Sheng  Yang, Shung-Haur 
Citation: Teng HW, etal., J Surg Oncol. 2012 Aug 1;106(2):123-9. doi: 10.1002/jso.23063. Epub 2012 Feb 13.
Pubmed: (View Article at PubMed) PMID:22331825
DOI: Full-text: DOI:10.1002/jso.23063


BACKGROUND AND OBJECTIVES: In metastatic colorectal cancer, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is a predictive biomarker for anti-epidermal growth factor receptor (EGFR) treatment and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) is a prognostic biomarker. We aimed to determine the impact of KRAS and BRAF mutation as determined from liver metastases specimens on overall survival (OS) in patients following colorectal liver metastasectomy.
METHODS: Liver metastases specimens (n = 292) obtained from patients after liver metastasectomy were used to determine the KRAS/BRAF genotype. Associations between clinicopathological parameters and KRAS/BRAF genotype were identified by univariate and multivariate analyses using the Cox proportional hazards model. The impact of KRAS/BRAF genotype on survival was analyzed using the Kaplan-Meier method.
RESULTS: The 5-year survival rate of the cohort was 55.8%. The KRAS and BRAF mutation rates were 38.0 and 2.1%, respectively. BRAF genotype, but not KRAS, was found to be an independent prognostic biomarker (HR = 5.181, P = 0.002) after adjustment for other significant confounding clinicopathological variates: Number of liver metastases (HR = 1.983, P = 0.009), concomitant extrahepatic disease (HR = 1.858, P = 0.014), and surgical margin (HR = 3.241, P < 0.001). BRAF genotype was an independent prognostic biomarker in patients with liver metastases only after metastasectomy (HR = 6.245, P < 0.003).
CONCLUSIONS: BRAF mutation is an independent prognostic biomarker for colorectal liver metastasectomy.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 18337265
Created: 2020-01-17
Species: All species
Last Modified: 2020-01-17
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.